Caldera says third study of PSA-test alternative shows high ability to spot Prostate cancer

Caldera Health, a New Zealand biotech company working on a gene-sequencing replacement for the world’s most widely used prostate cancer test, says its third clinical test has shown a strong ability to identify prostate cancer and screen out those who test negative.

The company is working on a replacement for the widely used PSA blood test with a simple “pee in a pot” test, using RNA biomarkers. In 2012, the US Preventive Services Task Force recommended against mass PSA screening because it threw up both false positives and negatives, didn’t distinguish between aggressive cancers and benign strains or even other prostate conditions, and led to over-diagnosis and unnecessary prostatectomies.

Read more

« »

Lead Partners

NZTE NZGCP PWC ATEED “NZX”

Expert Partner

AVID “Jarden”

AANZ Summit Sponsors

“UniServices” Kiwinet “AWS” “BNZ” “Momentum” “Hillfarrance” “Punakaiki” “MBIE” “GD1” “TompkinsWake” Callaghan Innovation